Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Terns Pharmaceuticals (TERN)
NASDAQ:TERN
RESEARCH TOOLSreports
Holding TERN?
Track your performance easily
TERN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.32 - $11.40
Previous CloseN/A
Volume294.76K
Average Volume (3M)1.78M
Market Cap
$382.22M
Enterprise Value$277.54M
Total Cash (Recent Filing)$86.88M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.39
Next Earnings
Apr 01, 2025EPS Estimate
-0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.18
Shares Outstanding84,938,860
10 Day Avg. Volume1,636,788
30 Day Avg. Volume1,779,322
Standard Deviation0.29
R-Squared0.00290
Alpha0.00939
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-5.80
P/FCF Ratio0.00
Enterprise Value/Market Cap0.73
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-2.64
Forecast
1Y Price Target
$17.50Price Target Upside292.38% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Terns Pharmaceuticals News
PremiumCompany Announcements
Terns Pharmaceuticals Reports Promising Results in CML Trial
PremiumCompany Announcements
Terns Pharmaceuticals Appoints Heather Turner to Board
PremiumCompany Announcements
Terns Pharmaceuticals Reports Q3 Progress and Financials
Bulls Say, Bears Say
Bulls Say
Chronic Myeloid Leukemia TreatmentInitial Phase 1 data for TERN-701 in chronic myeloid leukemia is promising, with no dose-limiting toxicities observed and the treatment demonstrating positive trends in efficacy for refractory patients, positioning it as a potential best-in-class treatment.
Financial Stability And Market OpportunitiesTerns Pharmaceuticals' strong financial position, with a cash runway extending to 2028, supports its ongoing developments in major market opportunities like obesity and chronic myeloid leukemia, enhancing its growth prospects.
Obesity TreatmentTerns Pharmaceuticals is making strides in the obesity field with its oral GLP-1 receptor agonist, TERN-601, showing competitive weight loss results and a favorable tolerability profile, indicating potential as a strong player in the market.
Bears Say
Adverse EventsTERN-601 treatment at the 740 mg dose resulted in the highest incidence of Grade 2 (moderate) adverse events, which were mostly gastrointestinal in nature.
Competitive LandscapeThe shares of Terns Pharmaceuticals, Inc. experienced a 15% decline due to competitive landscape news in the obesity market.
Partnership PotentialThe sell-off reflected diminished investor optimism around TERN's ability to land a major global pharma partner for its TERN-601 asset.
---
Ownership Overview
16.35% Insiders
8.96% Mutual Funds
0.41% Other Institutional Investors
65.52% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
TERN FAQ
What was Terns Pharmaceuticals’s price range in the past 12 months?
Terns Pharmaceuticals lowest stock price was $4.32 and its highest was $11.40 in the past 12 months.
What is Terns Pharmaceuticals’s market cap?
Terns Pharmaceuticals’s market cap is $382.22M.
When is Terns Pharmaceuticals’s upcoming earnings report date?
Terns Pharmaceuticals’s upcoming earnings report date is Apr 01, 2025 which is in 61 days.
How were Terns Pharmaceuticals’s earnings last quarter?
Terns Pharmaceuticals released its earnings results on Nov 12, 2024. The company reported -$0.28 earnings per share for the quarter, beating the consensus estimate of -$0.32 by $0.04.
Is Terns Pharmaceuticals overvalued?
According to Wall Street analysts Terns Pharmaceuticals’s price is currently Undervalued.
Does Terns Pharmaceuticals pay dividends?
Terns Pharmaceuticals does not currently pay dividends.
What is Terns Pharmaceuticals’s EPS estimate?
Terns Pharmaceuticals’s EPS estimate is -0.3.
How many shares outstanding does Terns Pharmaceuticals have?
Terns Pharmaceuticals has 84,938,860 shares outstanding.
What happened to Terns Pharmaceuticals’s price movement after its last earnings report?
Terns Pharmaceuticals reported an EPS of -$0.28 in its last earnings report, beating expectations of -$0.32. Following the earnings report the stock price went down -5.439%.
Which hedge fund is a major shareholder of Terns Pharmaceuticals?
Among the largest hedge funds holding Terns Pharmaceuticals’s share is Driehaus Capital Management LLC. It holds Terns Pharmaceuticals’s shares valued at 17M.
---
Terns Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$17.50 (292.38% Upside)
$17.50 (292.38% Upside)
Blogger Sentiment
Bullish
TERN Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 317.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $107.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 4.0%
Last 30 Days ▼ 4.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-16.66%
12-Months-Change
Fundamentals
Return on Equity
-28.28%
Trailing 12-Months
Asset Growth
39.22%
Trailing 12-Months
Company Description
Terns Pharmaceuticals
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases.
---
TERN Stock 12 Month Forecast
Average Price Target
$17.50
▲(292.38% Upside)
Technical Analysis
Madrigal Pharmaceuticals
―
Viking Therapeutics
―
Ensysce Biosciences
―
Genfit SA
―
Akero Therapeutics
―
Best Analysts Covering TERN
1 Year
1 Year Success Rate
4/10 ratings generated profit
1 Year Average Return
-2.61%
initiated a buy rating 3 months ago
Copying Etzer Darout's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of -2.61% per trade.
---